TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting

Phase 2

FDA Approved DrugsTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Sponsor:

American Society of Clinical Oncology

Code:

NCT02693535

Conditions

Lymphoma, Non-Hodgkin

Multiple Myeloma

Advanced Solid Tumors

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Palbociclib

Sunitinib

Temsirolimus

Trastuzumab and Pertuzumab

Vemurafenib and Cobimetinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-25. This information was provided to ClinicalTrials.gov by American Society of Clinical Oncology on 2025-05-06.